Keen, Harry, MD (1925-2013)

Harry Keen was the foremost British clinician involved in the epidemiology and trials of Type II diabetes, and in his trials found tolbutamide effective in reducing CVD risk, rescuing the reputation of oral agents after the UGDP trial.